Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
small molecule |
| gptkbp:approvalYear |
2020
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
L02BX07
|
| gptkbp:brand |
gptkb:Orgovyx
gptkb:Relumina |
| gptkbp:CASNumber |
737789-87-6
|
| gptkbp:chemicalClass |
non-peptide
|
| gptkbp:developer |
gptkb:Takeda_Pharmaceutical_Company
gptkb:Myovant_Sciences |
| gptkbp:hasMolecularFormula |
C29H27F2N7O5
|
| https://www.w3.org/2000/01/rdf-schema#label |
relugolix
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
GnRH receptor antagonist
|
| gptkbp:pregnancyCategory |
not for use in pregnancy
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
fatigue
headache decreased libido sweating hot flashes musculoskeletal pain |
| gptkbp:usedFor |
prostate cancer
endometriosis uterine fibroids |
| gptkbp:bfsParent |
gptkb:Roivant_Sciences
|
| gptkbp:bfsLayer |
5
|